tiprankstipranks
Advertisement
Advertisement
Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
PremiumRatingsBalanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
1M ago
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
Premium
Ratings
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
1M ago
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
Premium
The Fly
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
1M ago
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
PremiumRatingsBalancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
3M ago
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
Premium
The Fly
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
3M ago
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
Premium
The Fly
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100